213027-19-1
213027-19-1 結(jié)構(gòu)式
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-106993 | Cipralisant Cipralisant | 213027-19-1 | 1 mg | 2340元 |
| 2026/06/05 | HY-106993 | Cipralisant Cipralisant | 213027-19-1 | 5 mg | 5848元 |
| 2026/06/05 | HY-106993 | Cipralisant Cipralisant | 213027-19-1 | 10 mM * 1 mL in DMSO | 6432元 |
常見問題列表
pKi: 9.9 (Histamine H3 receptor)
Ki: 0.47 nM (Rat histamine H3 receptor)
Cipralisant (GT-2331) is a potent histamine H3 receptor antagonist with a pK i of 9.9 and a K i of 0.47 nM for rat histamine H3 receptor. Cipralisant acts as a full agonist at the recombinant rat histamine H3 receptor in vitro, and potently inhibits forskolin-induced cAMP accumulation with an EC 50 of 0.23 nM. Cipralisant increases the basal [ 35 S]GTPγS binding activities in membranes from HEK cells expressing the rat histamine H3 receptor (EC 50 , 5.6 nM).
Cipralisant (GT-2331) acts as an antagonist of histamine H3 receptor, and blocks R-α-methylhistamine (a histamine H3 receptor agonist)-induced water intake at 10 mg/kg via oral administration in rats.
